William Meury
Chief Executive Officer at Incyte Corp.
Sits on 2 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Syndax Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Syndax Pharmaceuticals Inc. May 14, 202486.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | Incyte Corp. | Grant or award | +26,807 | — | — |
| Jul 2, 2026 | Incyte Corp. | Shares withheld for tax | −4,779 | $116.86 | $558,474 |
| Apr 15, 2026 | Incyte Corp. | Option exercise | +125,000 | — | — |
| Jul 2, 2025 | Incyte Corp. | Grant or award | +36,101 | — | — |
| Feb 5, 2025 | Syndax Pharmaceuticals Inc. | Grant or award | +25,000 | — | — |
| Feb 7, 2024 | Syndax Pharmaceuticals Inc. | Grant or award | +17,000 | — | — |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +35,000 | $7.11 | $248,850 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −35,000 | $20.46 | $716,100 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +24,000 | $7.88 | $189,120 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −24,000 | $20.46 | $491,040 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +24,000 | $9.47 | $227,280 |
| Aug 2, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −24,000 | $20.45 | $490,800 |
| Feb 2, 2023 | Syndax Pharmaceuticals Inc. | Grant or award | +16,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.